Spinal muscular atrophy—recent therapeutic advances for an old challenge (original) (raw)

• Werdnig, G. Two early infantile hereditary cases of progressive muscular atrophy simulating dystrophy, but on a neural basis. 1891. Arch. Neurol. 25, 276–278 (1971).
  Article CAS PubMed Google Scholar
• Brzustowicz, L. M. et al. Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2–133. Nature 344, 540–541 (1990).
  Article CAS PubMed Google Scholar
• Arnold, W. D., Kassar, D. & Kissel, J. T. Spinal muscular atrophy: diagnosis and management in a new therapeutic era. Muscle Nerve 51, 157–167 (2014).
  Article PubMed PubMed Central CAS Google Scholar
• Darras, B. T. Non-5q spinal muscular atrophies: the alphanumeric soup thickens. Neurology 77, 312–314 (2011).
  Article PubMed Google Scholar
• Rossor, A. M. et al. Phenotypic and molecular insights into spinal muscular atrophy due to mutations in BICD2. Brain 138, 293–310 (2014).
  Article PubMed PubMed Central Google Scholar
• Sugarman, E. A. et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens. Eur. J. Hum. Genet. 20, 27–32 (2012).
  Article PubMed Google Scholar
• Prior, T. W. et al. Newborn and carrier screening for spinal muscular atrophy. Am. J. Med. Genet. A. 152A, 1608–1616 (2010).
  Article CAS PubMed Google Scholar
• Finkel, R. S. et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology 83, 810–817 (2014).
  Article PubMed PubMed Central Google Scholar
• Munsat, T. L. & Davies, K. E. International SMA consortium meeting. (26–28 June 1992, Bonn, Germany). Neuromuscul. Disord. 2, 423–428 (1992).
  Article CAS PubMed Google Scholar
• Feldkötter, M., Schwarzer, V., Wirth, R., Wienker, T. F. & Wirth, B. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am. J. Hum. Genet. 70, 358–368 (2002).
  Article PubMed Google Scholar
• Cho, S. & Dreyfuss, G. A degron created by SMN2 exon 7 skipping is a principal contributor to spinal muscular atrophy severity. Genes Dev. 24, 438–442 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Mercuri, E., Bertini, E. & Iannaccone, S. T. Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurol. 11, 443–452 (2012).
  Article PubMed Google Scholar
• Wang, C. H. et al. Consensus statement for standard of care in spinal muscular atrophy. J. Child. Neurol. 22, 1027–1049 (2007).
  Article PubMed Google Scholar
• Shababi, M. et al. Cardiac defects contribute to the pathology of spinal muscular atrophy models. Hum. Mol. Genet. 19, 4059–4071 (2010).
  Article CAS PubMed Google Scholar
• Rudnik-Schöneborn, S. et al. Congenital heart disease is a feature of severe infantile spinal muscular atrophy. J. Med. Genet. 45, 635–638 (2008).
  Article PubMed Google Scholar
• Palladino, A. et al. Cardiac involvement in patients with spinal muscular atrophies. Acta Myol. 30, 175–178 (2011).
  PubMed PubMed Central Google Scholar
• Iannaccone, S. T. Modern management of spinal muscular atrophy. J. Child. Neurol. 22, 974–978 (2007).
  Article PubMed Google Scholar
• Durkin, E. T., Schroth, M. K., Helin, M. & Shaaban, A. F. Early laparoscopic fundoplication and gastrostomy in infants with spinal muscular atrophy type I. J. Pediatr. Surg. 43, 2031–2037 (2008).
  Article PubMed Google Scholar
• Joyce, N. C., Hache, L. P. & Clemens, P. R. Bone health and associated metabolic complications in neuromuscular diseases. Phys. Med. Rehabil. Clin. N. Am. 23, 773–799 (2012).
  Article PubMed PubMed Central Google Scholar
• Verrillo, E. et al. Sleep architecture in infants with spinal muscular atrophy type 1. Sleep Med. 15, 1246–1250 (2014).
  Article PubMed Google Scholar
• Kaufmann, P. et al. Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year. Arch. Neurol. 68, 779–786 (2011).
  Article PubMed Google Scholar
• Yuan, P. & Jiang, L. Clinical characteristics of three subtypes of spinal muscular atrophy in children. Brain Dev. 37, 537–541 (2014).
  Article PubMed Google Scholar
• Piepers, S. et al. A natural history study of late onset spinal muscular atrophy types 3b and 4. J. Neurol. 255, 1400–1404 (2008).
  Article CAS PubMed Google Scholar
• Prior, T. W., Nagan, N., Sugarman, E. A., Batish, S. D. & Braastad, C. Technical standards and guidelines for spinal muscular atrophy testing. Genet. Med. 13, 686–694 (2011).
  Article PubMed Google Scholar
• Rudnik–Schöneborn, S. et al. Clinical utility gene card for: proximal spinal muscular atrophy. Eur. J. Hum. Genet. 20, (2012).
  Article CAS Google Scholar
• D'Amico, A., Mercuri, E., Tiziano, F. D. & Bertini, E. Spinal muscular atrophy. Orphanet J. Rare Dis. 6, 71 (2011).
  Article PubMed PubMed Central Google Scholar
• Vilchis, Z. et al. The high frequency of genetic diseases in hypotonic infants referred by neuropediatrics. Am. J. Med. Genet. A. 164A, 1702–1705 (2014).
  Article PubMed Google Scholar
• Lefebvre, S. et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80, 155–165 (1995).
  Article CAS PubMed Google Scholar
• Ogino, S. & Wilson, R. B. Genetic testing and risk assessment for spinal muscular atrophy (SMA). Hum. Genet. 111, 477–500 (2002).
  Article CAS PubMed Google Scholar
• Scully, M. A., Farrell, P. M., Ciafaloni, E., Griggs, R. C. & Kwon, J. M. Cystic fibrosis newborn screening: a model for neuromuscular disease screening? Ann. Neurol. 77, 189–197 (2014).
  Article PubMed CAS Google Scholar
• Swoboda, K. J. SMN-targeted therapeutics for spinal muscular atrophy: are we SMArt enough yet? J. Clin. Invest. 124, 487–490 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Kolb, S. J. NeuroNEXT SMA biomarkers study. Ann. Neurol. 74, A8 (2013).
  Article PubMed Google Scholar
• Castro, D. & Iannaccone, S. T. Spinal muscular atrophy: therapeutic strategies. Curr. Treat. Options Neurol. 16, 316 (2014).
  Article PubMed Google Scholar
• Monani, U. R. et al. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum. Mol. Genet. 8, 1177–1183 (1999).
  Article CAS PubMed Google Scholar
• Lorson, C. L., Hahnen, E., Androphy, E. J. & Wirth, B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc. Natl Acad. Sci. USA 96, 6307–6311 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Burnett, B. G. et al. Regulation of SMN protein stability. Mol. Cell. Biol. 29, 1107–1115 (2009).
  Article CAS PubMed Google Scholar
• Elsheikh, B. et al. An analysis of disease severity based on SMN2 copy number in adults with spinal muscular atrophy. Muscle Nerve 40, 652–656 (2009).
  Article PubMed Google Scholar
• Prior, T. W., Swoboda, K. J., Scott, H. D. & Hejmanowski, A. Q. Homozygous SMN1 deletions in unaffected family members and modification of the phenotype by SMN2. Am. J. Med. Genet. A. 130A, 307–310 (2004).
  Article PubMed Google Scholar
• Schrank, B. et al. Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc. Natl Acad. Sci. USA 94, 9920–9925 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Monani, U. R. et al. The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy. Hum. Mol. Genet. 9, 333–339 (2000).
  Article CAS PubMed Google Scholar
• Le, T. T. et al. SMNΔ7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum. Mol. Genet. 14, 845–857 (2005).
  Article CAS PubMed Google Scholar
• Bevan, A. K. et al. Early heart failure in the SMNΔ7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery. Hum. Mol. Genet. 19, 3895–3905 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Butchbach, M. E. R., Edwards, J. D., Schussler, K. R. & Burghes, A. H. A novel method for oral delivery of drug compounds to the neonatal SMNΔ7 mouse model of spinal muscular atrophy. J. Neurosci. Methods 161, 285–290 (2007).
  Article CAS PubMed Google Scholar
• Foust, K. D. et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat. Biotechnol. 28, 271–274 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Dominguez, E. et al. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum. Mol. Genet. 20, 681–693 (2011).
  Article CAS PubMed Google Scholar
• Cherry, J. J. et al. Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug-like compounds. EMBO Mol. Med. 5, 1035–1050 (2013).
  Article CAS PubMed Central Google Scholar
• Ebert, A. D. et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 457, 277–280 (2009).
  Article CAS PubMed Google Scholar
• Sareen, D. et al. Inhibition of apoptosis blocks human motor neuron cell death in a stem cell model of spinal muscular atrophy. PLoS ONE 7, e39113 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Corti, S. et al. Genetic correction of human induced pluripotent stem cells from patients with spinal muscular atrophy. Sci. Transl. Med. 4, 165ra162 (2012).
  Article PubMed PubMed Central CAS Google Scholar
• Vitte, J. et al. Refined characterization of the expression and stability of the SMN gene products. Am. J. Pathol. 171, 1269–1280 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Wang, J. & Dreyfuss, G. A cell system with targeted disruption of the SMN gene: functional conservation of the SMN protein and dependence of Gemin2 on SMN. J. Biol. Chem. 276, 9599–9605 (2001).
  Article CAS PubMed Google Scholar
• Pellizzoni, L., Kataoka, N., Charroux, B. & Dreyfuss, G. A novel function for SMN, the spinal muscular atrophy disease gene product, in pre-mRNA splicing. Cell 95, 615–624 (1998).
  Article CAS PubMed Google Scholar
• Eggert, C., Chari, A., Laggerbauer, B. & Fischer, U. Spinal muscular atrophy: the RNP connection. Trends Mol. Med. 12, 113–121 (2006).
  Article CAS PubMed Google Scholar
• Pellizzoni, L. Chaperoning ribonucleoprotein biogenesis in health and disease. EMBO Rep. 8, 340–345 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Chari, A. et al. An assembly chaperone collaborates with the SMN complex to generate spliceosomal SnRNPs. Cell 135, 497–509 (2008).
  Article CAS PubMed Google Scholar
• Battle, D. J. et al. The SMN complex: an assembly machine for RNPs. Cold Spring Harb. Symp. Quant. Biol. 71, 313–320 (2006).
  Article CAS PubMed Google Scholar
• Kolb, S. J., Battle, D. J. & Dreyfuss, G. Molecular functions of the SMN complex. J. Child. Neurol. 22, 990–994 (2007).
  Article PubMed Google Scholar
• Gabanella, F. et al. Ribonucleoprotein assembly defects correlate with spinal muscular atrophy severity and preferentially affect a subset of spliceosomal snRNPs. PLoS ONE 2, e921 (2007).
  Article PubMed PubMed Central CAS Google Scholar
• Gabanella, F., Carissimi, C., Usiello, A. & Pellizzoni, L. The activity of the spinal muscular atrophy protein is regulated during development and cellular differentiation. Hum. Mol. Genet. 14, 3629–3642 (2005).
  Article CAS PubMed Google Scholar
• Burghes, A. H. & Beattie, C. E. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? Nat. Rev. Neurosci. 10, 597–609 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Boulisfane, N. et al. Impaired minor tri-snRNP assembly generates differential splicing defects of U12-type introns in lymphoblasts derived from a type I SMA patient. Hum. Mol. Genet. 20, 641–648 (2011).
  Article CAS PubMed Google Scholar
• Pellizzoni, L., Yong, J. & Dreyfuss, G. Essential role for the SMN complex in the specificity of snRNP assembly. Science 298, 1775–1779 (2002).
  Article CAS PubMed Google Scholar
• Zhang, Z. et al. SMN deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in splicing. Cell 133, 585–600 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Li, D. K., Tisdale, S., Lotti, F. & Pellizzoni, L. SMN control of RNP assembly: from post-transcriptional gene regulation to motor neuron disease. Semin. Cell Dev. Biol. 32, 22–29 (2014).
  Article CAS PubMed Google Scholar
• Kariya, S. et al. Requirement of enhanced survival motoneuron protein imposed during neuromuscular junction maturation. J. Clin. Invest. 124, 785–800 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Oprea, G. E. et al. Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy. Science 320, 524–527 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• McWhorter, M. L., Monani, U. R., Burghes, A. H. & Beattie, C. E. Knockdown of the survival motor neuron (Smn) protein in zebrafish causes defects in motor axon outgrowth and pathfinding. J. Cell Biol. 162, 919–931 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Rossoll, W. et al. Specific interaction of Smn, the spinal muscular atrophy determining gene product, with hnRNP-R and gry-rbp/hnRNP-Q: a role for Smn in RNA processing in motor axons? Hum. Mol. Genet. 11, 93–105 (2002).
  Article CAS PubMed Google Scholar
• Rossoll, W. & Bassell, G. J. Spinal muscular atrophy and a model for survival of motor neuron protein function in axonal ribonucleoprotein complexes. Results Probl. Cell Differ. 48, 289–326 (2009).
  CAS PubMed PubMed Central Google Scholar
• Hubers, L. et al. HuD interacts with survival motor neuron protein and can rescue spinal muscular atrophy-like neuronal defects. Hum. Mol. Genet. 20, 553–579 (2011).
  Article CAS PubMed Google Scholar
• Martinez, T. L. et al. Survival motor neuron protein in motor neurons determines synaptic integrity in spinal muscular atrophy. J. Neurosci. 32, 8703–8715 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Goulet, B. B., Kothary, R. & Parks, R. J. At the “junction” of spinal muscular atrophy pathogenesis: the role of neuromuscular junction dysfunction in SMA disease progression. Curr. Mol. Med. 13, 1160–1174 (2013).
  Article CAS PubMed Google Scholar
• Fayzullina, S. & Martin, L. J. Skeletal muscle DNA damage precedes spinal motor neuron DNA damage in a mouse model of spinal muscular atrophy (SMA). PLoS ONE 9, e93329 (2014).
  Article PubMed PubMed Central CAS Google Scholar
• Boyer, J. G. et al. Early onset muscle weakness and disruption of muscle proteins in mouse models of spinal muscular atrophy. Skelet. Muscle 3, 24 (2013).
  Article PubMed PubMed Central CAS Google Scholar
• Hunter, G., Aghamaleky Sarvestany, A., Roche, S. L., Symes, R. C. & Gillingwater, T. H. SMN-dependent intrinsic defects in Schwann cells in mouse models of spinal muscular atrophy. Hum. Mol. Genet. 23, 2235–2250 (2014).
  Article CAS PubMed Google Scholar
• Imlach, W. L. et al. SMN is required for sensory-motor circuit function in Drosophila. Cell 151, 427–439 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Prior, T. W. et al. A positive modifier of spinal muscular atrophy in the SMN2 gene. Am. J. Hum. Genet. 85, 408–413 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Jarecki, J. et al. Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy. Hum. Mol. Genet. 14, 2003–2018 (2005).
  Article CAS PubMed Google Scholar
• Cherry, J. J. et al. Assays for the identification and prioritization of drug candidates for spinal muscular atrophy. Assay Drug Dev. Technol. 12, 315–341 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Lorson, M. A. & Lorson, C. L. SMN-inducing compounds for the treatment of spinal muscular atrophy. Future Med. Chem. 4, 2067–2084 (2012).
  Article CAS PubMed Google Scholar
• Thurmond, J. et al. Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy. J. Med. Chem. 51, 449–469 (2008).
  Article CAS PubMed Google Scholar
• Yuo, C.-Y., Lin, H.-H., Chang, Y.-S., Yang, W.-K. & Chang, J.-G. 5-(N-ethyl-N-isopropyl)-amiloride enhances SMN2 exon 7 inclusion and protein expression in spinal muscular atrophy cells. Ann. Neurol. 63, 26–34 (2008).
  Article CAS PubMed Google Scholar
• Bowerman, M., Murray, L. M., Boyer, J. G., Anderson, C. L. & Kothary, R. Fasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy. BMC Med. 10, 24 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Bowerman, M., Beauvais, A., Anderson, C. L. & Kothary, R. Rho-kinase inactivation prolongs survival of an intermediate SMA mouse model. Hum. Mol. Genet. 19, 1468–1478 (2010).
  Article CAS PubMed Google Scholar
• Miller, R. G. et al. A placebo-controlled trial of gabapentin in spinal muscular atrophy. J. Neurol. Sci. 191, 127–131 (2001).
  Article CAS PubMed Google Scholar
• Wirth, B., Garbes, L. & Riessland, M. How genetic modifiers influence the phenotype of spinal muscular atrophy and suggest future therapeutic approaches. Curr. Opin. Genet. Dev. 23, 330–338 (2013).
  Article CAS PubMed Google Scholar
• Swoboda, K. J. et al. Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann. Neurol. 57, 704–712 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Passini, M. A. et al. CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J. Clin. Invest. 120, 1253–1264 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Valori, C. F. et al. Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci. Transl. Med. 2, 35ra42 (2010).
  Article PubMed CAS Google Scholar
• Mitrpant, C. et al. Improved antisense oligonucleotide design to suppress aberrant SMN2 gene transcript processing: towards a treatment for spinal muscular atrophy. PLoS ONE 8, e62114 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Duque, S. I. et al. A large animal model of spinal muscular atrophy and correction of phenotype. Ann. Neurol. 77, 399–414 (2014).
  Article CAS Google Scholar
• Gray, S. J., Nagabhushan Kalburgi, S., McCown, T. J. & Jude Samulski, R. Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther. 20, 450–459 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Foust, K. D. et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 27, 59–65 (2009).
  Article CAS PubMed Google Scholar
• Bevan, A. K. et al. Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol. Ther. 19, 1971–1980 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Meyer, K. et al. Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates. Mol. Ther. 23, 477–487 (2014).
  Article PubMed PubMed Central CAS Google Scholar
• Asokan, A., Schaffer, D. V. & Jude Samulski, R. The AAV vector toolkit: poised at the clinical crossroads. Mol. Ther. 20, 699–708 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Singh, N. K., Singh, N. N., Androphy, E. J. & Singh, R. N. Splicing of a critical exon of human survival motor neuron is regulated by a unique silencer element located in the last intron. Mol. Cell. Biol. 26, 1333–1346 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Williams, J. H. et al. Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy. J. Neurosci. 29, 7633–7638 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Passini, M. A. et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci. Transl. Med. 3, 72ra18 (2011).
  Article PubMed PubMed Central Google Scholar
• Hua, Y. et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev. 24, 1634–1644 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Keil, J. M. et al. A short antisense oligonucleotide ameliorates symptoms of severe mouse models of spinal muscular atrophy. Mol. Ther. Nucleic Acids 3, e174 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Mitrpant, C. et al. Improved antisense oligonucleotide design to suppress aberrant SMN2 gene transcript processing: towards a treatment for spinal muscular atrophy. PLoS ONE 8, e62114 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Hua, Y. et al. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 478, 123–126 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Zhou, H. et al. A novel morpholino oligomer targeting ISS-N1 improves rescue of severe spinal muscular atrophy transgenic mice. Hum. Gene Ther. 24, 331–342 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Osman, E. Y. et al. Morpholino antisense oligonucleotides targeting intronic repressor Element1 improve phenotype in SMA mouse models. Hum. Mol. Genet. 23, 4832–4845 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Rigo, F. et al. Pharmacology of a central nervous system delivered 2′-_O_-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates. J. Pharmacol. Exp. Ther. 350, 46–55 (2014).
  Article PubMed PubMed Central CAS Google Scholar
• Nizzardo, M. et al. Effect of combined systemic and local morpholino treatment on the spinal muscular atrophy Δ7 mouse model phenotype. Clin. Ther. 36, 340–356.e5 (2014).
  Article CAS PubMed Google Scholar
• Titus, S. et al. High throughput screening for SMA. Probe Reports from the NIH Molecular Libraries Program [online], (2010).
  Google Scholar
• Makhortova, N. R. et al. A screen for regulators of survival of motor neuron protein levels. Nat. Chem. Biol. 7, 544–552 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Hastings, M. L. et al. Tetracyclines that promote SMN2 exon 7 splicing as therapeutics for spinal muscular atrophy. Sci. Transl. Med. 1, 5ra12 (2009).
  Article PubMed PubMed Central Google Scholar
• Naryshkin, N. A. et al. Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science 345, 688–693 (2014).
  CAS PubMed Google Scholar